

The Valens Company

09:29 23 Dec 2019

The Valens Company strikes two new multi-year supply and extraction deals

Valens GroWorks Corp (CVE:VLNS) (OTCMKTS:VLNCF) announced two major multi-year extraction and supply deals on Monday, its first moves since rebranding to The Valens Company.

The first deal with cannabis producer Emerald Health Therapeutics Inc (CVE:EMH) will see Valens process cannabis and hemp biomass into resins and distillates.

Under a separate agreement, Valens will supply edibles producer Dynaleo with distillate to use in the production of CBD ingestible products.

READ: Valens GroWorks rebrands to The Valens Company

In the Emerald deal, Valens signed a four-year deal that sees the extraction company processing a minimum of 10,000 kilograms per year of cannabis and hemp biomass, supplied by Emerald.

Valens will process the biomass into resins and distillates on a fee-for-service basis.

In addition, Valens will supply Emerald with white label services such as formulation, mixing and filing for products like vaporizers, softgels and tinctures.

The deal is expected to kick off in the first quarter of 2020.

"We are excited to partner with Emerald Health to provide our extraction and white label expertise to bolster their product platform," said Tyler Robson, CEO of The Valens Company, calling Emerald Health "one of the industry's leading players."

Emerald Health's CEO Riaz Bandali said the company was excited to have Valens onboard as a strategic partner. "Beyond being an industry leader in extraction, formulation, and other services, Valens' cost-effective end-to-end fulfillment solution can help transition our novel product ideas into tangible products in a faster and more cost-effective manner," Bandali said in a statement.

Dynaleo deal

The deal with Dynaleo, meanwhile, sees Valens supplying the edibles producer with distillate or S?RSE emulsions containing a minimum of 40 kilograms of active THC or CBD cannabinoids, the company told investors.

The agreement has an initial two-year term with two automatic one-year renewals. During the third year of the deal, Dynaleo will purchase at least 50 kilograms in distillate or S?RSE emulsions and 75 kilograms in the fourth year.

According to the terms, if Dynaleo decides to receive emulsified, high-potency cannabis oil, it will be processed using

Price: 1.58

Market Cap: \$202.79 m

1 Year Share Price Graph



October 2019 April 2020 October 2020

Share Information

Code: VLNS

Listing: TSX

52 week	High	Low
	3.13	1.49

Sector: Cannabis

Website: thevalenscompany.com

Company Synopsis:

The Valens Company is a multi-licensed, vertically-integrated cannabis company focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and white-label product development.

action@proactiveinvestors.com

Valens' S?RSE technology for an additional charge.

READ: Valens widens exclusive licence pact to bring cannabis-infusion technology to new markets

Valens president Jeff Fallows said the company was excited to be working with Dynaleo on its edibles production.

"The team at Dynaleo have been active in the Canadian cannabis sector for many years advocating for safe, high-quality edibles for the adult use market," Fallows said in a statement. Fallows said that Valens will be supporting Dynaleo's operations with quality active cannabis inputs as Dynaleo builds a state-of-the-art, large scale facility due to come online in 2020.

The new facility gives Dynaleo the capacity to produce more than 400 million units in its first year of operations, according to Fallows.

Valens also said it had received regulatory approval to change its OTCQX ticker symbol to "VLNCF."

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of The Valens Company named herein, including the promotion by the Company of The Valens Company in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).